Fluvastatin: a choice for COVID-19 associated mucormycosis management

SARS-CoV-2 invades the respiratory tract epithelium and can result in systemic inflammation prior to an infection caused by either bacteria or fungus. COVID-19-associated mucormycosis (CAM) is a serious condition that can occur during the time of the disease due to increased administration of cortic...

Full description

Saved in:
Bibliographic Details
Published inCurrent medicinal chemistry
Main Authors Tavakkoli, Alireza, Johnston, Thomas P, Sahebkar, Amirhossein
Format Journal Article
LanguageEnglish
Published United Arab Emirates 06.07.2023
Subjects
COVID-19
Mucormycosis
Fluvastatin
Fungal infection
Statins
Immune system
Online AccessGet more information

Cover

More Information
Summary:SARS-CoV-2 invades the respiratory tract epithelium and can result in systemic inflammation prior to an infection caused by either bacteria or fungus. COVID-19-associated mucormycosis (CAM) is a serious condition that can occur during the time of the disease due to increased administration of corticosteroids. Various studies have suggested that statins may improve clinical outcomes in COVID-19 patients. According to several preclinical reports, fluvastatin was shown to exert direct and indirect synergistic antifungal activity. Thus, fluvastatin could be considered a potential antifungal agent when no other option is available. Furthermore, in comparison with other statins, fluvastatin exhibits the fewest drug/drug interactions with anti-Mucorales azoles (e.g., isavuconazole and posaconazole), as well as with medicines that are used in solid organ transplant recipients (e.g., cyclosporine) and HIV-positive individuals (e.g., ritonavir); two groups of patients that have a higher risk of infection with Mucorales fungi following a SARS-CoV-2 infection.
ISSN:1875-533X
DOI:10.2174/0929867331666230706152616